Reuters| London | United Kingdom
British drugmaker AstraZeneca said on Wednesday its cancer drug Lynparza has met the main goal of a late-stage study in patients with metastatic prostate cancer and have certain genetic mutations.
The company said Lynparza was successful in making patients who have metastatic castration-resistant prostate cancer and who have HRR gene mutations live longer without the disease worsening, compared with the standard of care.
Also Read: AstraZeneca moves US court against Dr Reddy's on generic
(This story has not been edited by Devdiscourse staff and is auto-generated from a syndicated feed.)
{{#Source}}{{Source}}{{/Source}}{{#IsBlog}}
{{Disclaimer}}
{{/Disclaimer}}